Taken together, TfR1 up-regulation is significantly associated with enhanced metastatic potential and worse clinical prognosis of RCC, implying that TfR1 expression data could be used in advance to select patients with RCC for whom ART could be a beneficial therapeutic agent. The gene discussed is TFRC; the disease is renal cell carcinoma.